Dr. David F. McDermott on Nivolumab in RCC

David F. McDermott, MD
Published: Friday, Aug 05, 2016


David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discuses nivolumab (Opdivo) in renal cell carcinoma (RCC).
 
In the phase III CheckMate-025 trial, nivolumab was significantly superior to everolimus (Afinitor) in patients who had failed prior antiangiogenic therapy, with improvements in overall survival (OS), quality of life, and safety.  
 
The phase trial is about the cleanest study that we have ever had in kidney cancer, said McDermott. There were clear improvements in overall survival (OS), quality of life, and safety. There were meaningful improvements and not just statistically significant improvements, he added.    
 
However, there are still challenges with the drug, said McDermott. Selection needs to be improved, as over one-third of patients don’t seem to benefit much from nivolumab.  
 
Combinations should also be considered, he said.   
 

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discuses nivolumab (Opdivo) in renal cell carcinoma (RCC).
 
In the phase III CheckMate-025 trial, nivolumab was significantly superior to everolimus (Afinitor) in patients who had failed prior antiangiogenic therapy, with improvements in overall survival (OS), quality of life, and safety.  
 
The phase trial is about the cleanest study that we have ever had in kidney cancer, said McDermott. There were clear improvements in overall survival (OS), quality of life, and safety. There were meaningful improvements and not just statistically significant improvements, he added.    
 
However, there are still challenges with the drug, said McDermott. Selection needs to be improved, as over one-third of patients don’t seem to benefit much from nivolumab.  
 
Combinations should also be considered, he said.   
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x